Naveen S. Basappa

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 163 citations · Full text

Medicine, Oncology, Pharmacology +10

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

Michael P. Chu, Sunita Ghosh, Carole Chambers et al. · Clinical Lung Cancer · 2014 · 104 citations

Medicine, Oncology, Pharmacology +13

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis

Janet Roberts, Michael Smylie, John Walker et al. · Clinical Rheumatology · 2019 · 68 citations

Medicine, Pharmacology, Pharmacotherapy +15